These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15790508)

  • 21. Steady state relations between control proteins regulating the formation of the alternative pathway C3 convertase.
    Reeve J; Woo PM
    Immunology; 1982 Aug; 46(4):859-66. PubMed ID: 6921154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.
    Fritzinger DC; Hew BE; Lee JQ; Newhouse J; Alam M; Ciallella JR; Bowers M; Gorsuch WB; Guikema BJ; Stahl GL; Vogel CW
    Adv Exp Med Biol; 2008; 632():293-307. PubMed ID: 19025130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
    Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
    Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivation of complement by recombinant human C3 derivatives.
    Spillner F; Kölln J; Bredehorst R
    Adv Exp Med Biol; 2006; 586():347-60. PubMed ID: 16893083
    [No Abstract]   [Full Text] [Related]  

  • 26. Complement C3 isoforms in Austrelaps superbus.
    Rehana S; Kini RM
    Toxicon; 2008 Apr; 51(5):864-81. PubMed ID: 18262580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.
    Rooijakkers SH; Ruyken M; Roos A; Daha MR; Presanis JS; Sim RB; van Wamel WJ; van Kessel KP; van Strijp JA
    Nat Immunol; 2005 Sep; 6(9):920-7. PubMed ID: 16086019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Soliakov LS; Zinchenko AA
    Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and characterization of the C345C/NTR domains of complement components C3 and C5.
    Thai CT; Ogata RT
    J Immunol; 2003 Dec; 171(12):6565-73. PubMed ID: 14662858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights into the central complement component C3.
    Janssen BJ; Gros P
    Mol Immunol; 2007 Jan; 44(1-3):3-10. PubMed ID: 16875735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flavoxobin, a serine protease from Trimeresurus flavoviridis (habu snake) venom, independently cleaves Arg726-Ser727 of human C3 and acts as a novel, heterologous C3 convertase.
    Yamamoto C; Tsuru D; Oda-Ueda N; Ohno M; Hattori S; Kim ST
    Immunology; 2002 Sep; 107(1):111-7. PubMed ID: 12225369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of classical C3 convertase of complement by tear lactoferrin.
    Kijlstra A; Jeurissen SH
    Immunology; 1982 Oct; 47(2):263-70. PubMed ID: 6922088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure and molecular genetics of complement proteins. An update.
    Volanakis JE
    Year Immunol; 1986; 2():164-76. PubMed ID: 3554821
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents.
    Fritzinger DC
    Hawaii Med J; 2005 May; 64(5):133-4, 137. PubMed ID: 15989147
    [No Abstract]   [Full Text] [Related]  

  • 37. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.
    Vogel CW; Fritzinger DC
    Toxicon; 2010 Dec; 56(7):1198-222. PubMed ID: 20417224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

  • 40. [Inhibition of formation of complement C5-convertase].
    Kozlov LV; Lebedeva TV
    Bioorg Khim; 1998 May; 24(5):350-5. PubMed ID: 9661788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.